GLP-1 Drugs and Skin Cancer Risk

A four-person dermatology research group, Rashwan Alameddine, Allison Roecker, Mohamad Jabin and Richard F. Wagner Jr., published a paper in Dermatologic Surgery on September 10, 2026, titled "Reduced Risk in Melanoma and Nonmelanoma Skin Cancers in Obese Patients on Semaglutide and Tirzepatide."^[1] The title states the finding outright: patients with obesity taking semaglutide or tirzepatide, the GLP-1 class drugs sold as Ozempic, Wegovy, Mounjaro and Zepbound, had a lower rate of both cancer types than the group the researchers compared them against^[1]. What the title does not tell you, and what we could not confirm because the paper's abstract is not public and the full text sits behind a journal subscription, is how large that reduction was, how many patients were studied, or exactly who made up the comparison group^[1].

What the new paper claims

Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery^[1]. The paper carries PubMed ID 42714323 and DOI 10.1097/DSS.0000000000005339, and as of this writing it is listed as published ahead of print^[1]. The same finding, under the identical title, reached a smaller audience first: three of the four authors, Mohamad Jabin, Rashwan Alameddine and Allison Roecker, alongside Renat Ahatov and Richard F. Wagner Jr., gave a resident podium presentation with this title at the Texas Dermatological Society's Spring 2026 meeting in Dallas in April, months before the peer-reviewed version appeared^[4]. That timeline tells you the finding has been circulating among dermatologists for a while. It does not tell you the methodology, the sample size, or the actual size of the risk reduction, because none of that appears in the publicly visible citation.

What the wider evidence on GLP-1 drugs and skin cancer says

This is not the first paper to ask whether GLP-1 receptor agonists change skin cancer risk, and the existing evidence is more cautious than the new title suggests. A 2026 target trial emulation by Tang and colleagues used the TriNetX health-records network to match new GLP-1 receptor agonist users against new SGLT2 inhibitor users (235,797 matched pairs) and against new DPP-4 inhibitor users (153,873 matched pairs), all in adults with type 2 diabetes^[2]. GLP-1 receptor agonist use was not associated with a higher melanoma risk: the hazard ratio was 1.04 against SGLT2 inhibitors and 1.09 against DPP-4 inhibitors, and neither confidence interval pointed convincingly toward harm^[2]. For nonmelanoma skin cancer, the researchers saw a borderline increase against SGLT2 inhibitors (hazard ratio 1.06), but that signal shrank to a hazard ratio of 0.98 once they recalibrated for residual bias using negative control outcomes, and the authors concluded it likely reflected bias rather than a real drug effect^[2]. A separate cohort, described in a 2025 review in the journal Diseases, compared about 11,700 GLP-1 receptor agonist users with roughly 208,000 sulfonylurea users and found no increase in melanoma risk (hazard ratio 0.96) and no increase in nonmelanoma skin cancer either^[3].

Why obesity drugs and cancer risk keep coming up together

Semaglutide and tirzepatide are both approved for chronic weight management, and both produce substantial weight loss in the trials that got them approved, detailed on our tirzepatide and semaglutide pages. Researchers have spent years asking whether that much weight loss changes cancer risk generally, and skin cancer sits in an odd spot within that question: its two best-known risk factors, ultraviolet exposure and immune suppression, have nothing obvious to do with body weight. That is part of why a reduced-risk finding, if it holds up, would need explaining rather than just reporting. It could reflect something about the drugs themselves, something about the weight loss they cause, or something about the patients who stay on treatment long enough to be counted, and the new paper's public citation does not tell us which.

What this is not

This is not a reason to start semaglutide or tirzepatide for cancer prevention, and no dermatologist or oncologist is recommending that based on one ahead-of-print paper. It is not proof of cause and effect. A lower rate of diagnosed skin cancer in a treated group can show up for reasons that have nothing to do with the drug itself: people who stay on an injectable weight-loss medicine tend to see doctors more often, which can mean more skin checks and earlier treatment of anything found, not necessarily fewer cancers forming in the first place.

Retrospective comparisons like this one cannot tell those explanations apart on their own, which is exactly the kind of gap the Tang team's negative-control calibration was designed to catch^[2]. And it is not dosing or prescribing guidance. If you are on either drug, or considering one, your skin cancer screening schedule and any questions about this paper belong in a conversation with your prescriber and your dermatologist, not with an article.

What we don't yet know

The biggest gap is the paper itself: its sample size, its comparison group, its statistical adjustment and its actual effect size are not in the public record as of this writing, because Dermatologic Surgery has not posted an abstract and the full text requires a subscription^[1]. Independent replication is the next real test, ideally with a design like Tang's target trial emulation, which is built specifically to strip out the kind of healthy-user bias that can turn a null result into a false positive in retrospective data^[2]. Until that happens, or until the full paper becomes available for a closer read, the honest summary is that one dermatology paper reports a reduced skin cancer risk in obese patients on semaglutide and tirzepatide, the broader GLP-1 literature so far reports no clear increase in either direction, and nobody has yet shown why the two drugs would lower skin cancer risk if the new finding replicates.